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ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and eco-
nomic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose 
a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody 
test and performed serology assessment of antibody response to SARS-CoV-2. In PCR- 
confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized 
patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in 
patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks 
disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also 
compared different blood sample types and suggest a higher sensitivity by serum/plasma 
over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples 
collected between 2016-2018. Our study provides a comprehensive validation of the rapid 
COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with 
disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG 
test may be applied to assess the COVID-19 status both at the individual and at a population 
level.
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Introduction
The coronavirus disease 2019 (COVID-19) is caused 
by infection of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). As of 2 June 2020, it 
had caused a total of 6,194,533 cases of infection and 
376,320 deaths worldwide[1]. The COVID-19 pan-
demic has become a global crisis, and the outbreak 
has had a substantial impact on the world economy. 
Resuming from society lockdown to normality 
depends largely on population screening of COVID- 
19 immunity, and serology assessment of antibody 
response to SARS-CoV-2 by blood antibody test is 
a crucial aid to track the true spread of the pandemic.
In the current clinical practice, the reverse tran-
scription-polymerase chain reaction (RT-PCR) is the 
most commonly used method for the diagnosis of 
COVID-19. The test is performed on upper respira-
tory tract specimens including nasopharyngeal and 
throat swabs. Although PCR offers detection of viral 
RNA, the result may not necessarily reflect the 
presence of viable virus[2]. False-negative rates up 
to 50% may occur due to inappropriate sampling 
procedure or timing in relation to disease onset 
[3,4]. Furthermore, PCR tests are also technically 
demanding and costly in operation. To compromise 
the limitation of the PCR test, COVID-19 infection 
can also be detected by serology assessment of anti-
body responses to SARS-CoV-2 infection. The anti-
body test captures the presence of antibodies both 
during and after the infection and is able to deter-
mine if a person has been infected with the virus, 
even without the development of symptoms. This is 
particularly important for individuals who present to 
the health care late after disease onset[5]. Blood anti-
body tests may therefore complement the PCR test to 
accurately diagnose a current or resolved infection, 
map the extent of community spread of COVID-19, 
and profile the potential protection from future virus 
exposure by acquired immunity.
In this study, we assessed antibody responses to 
SARS-CoV-2 in patients with COVID-19 by a rapid 
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COVID-19 IgM/IgG test. The evaluation was per-
formed on patients from the acute phase of the dis-
ease; as well as hospitalized and recovered COVID-19 
patients. The specificity of the test was verified on 
COVID-19 negative blood samples collected prior to 
the pandemic. We also tested whether different blood 
sample types (serum/plasma/whole blood) provided 
the same results for this assay.
Material and methods
Study cohorts and samples
COVID-19 cohort
Patients with RT-PCR verified COVID-19 were 
enrolled prospectively either in the convalescence 
phase (2–8 weeks after start of symptoms) or when 
they were acutely ill or/and hospitalized. The study 
was conducted at the Department for Infectious 
Diseases, Skåne University Hospital, Lund, Sweden. 
All patients gave their informed consent to partici-
pate in the study. Blood was drawn in serum tubes 
and analyzed directly or after coagulation overnight 
at 8°C followed by centrifugation at 2 000 g for 
10 minutes.
Muscle Satellite Cell Study (MSAT) cohort
The MSAT is an ongoing study since 2016 that 
recruits healthy male volunteers for exercise testing 
at the Department of Clinical Sciences, Malmö, Lund 
University, Sweden. All 39 MSAT serum samples 
included in this analysis were collected between 
2016 and 2017.
Carotid Plaque Imaging Project (CPIP) cohort
The CPIP is an ongoing cohort since 2006 that 
recruits patients undergoing carotid endarterectomy 
at Lund University Hospital to study atherosclerosis 
and inflammatory and immune markers. Blood sam-
ples were collected the day before surgery. For the 
current study, 30 serum samples collected between 
2016 and 2018 were included.
COVID-19 antibody test IgM/IgG
The serology assessment of COVID-19 antibodies 
was performed using ZetaGene COVID-19 Antibody 
Test IgM/IgG (ZetaGene, Sweden; www.zetagene. 
com). The ZetaGene COVID-19 Antibody Test IgM/ 
IgG is a lateral flow immunoassay intended for the 
qualitative detection and differentiation of IgM and 
IgG antibodies to SARS-CoV-2 in serum, plasma, or 
whole blood samples from patients suspected of 
COVID-19 infection.
The test cassette consists of: (1) a conjugate pad 
containing SARS-CoV-2 RBD antigen and rabbit 
IgG; (2) a nitrocellulose membrane containing IgG 
line (G) and IgM line (M) coated with anti-human 
IgG or IgM; and a control line (C) coated with goat 
anti-rabbit IgG. When the test sample is dispensed 
into the sample well of the test cassette, the speci-
men migrates along the cassette. A negative anti-
body test result is defined as no additional line to 
the presence of C line. A positive antibody test 
result is defined as visible G or M line or both in 
addition to the presence of a C line.
The antibody assessment was conducted according 
to the manufacturer’s instruction (www.zetagene. 
com). In brief, 10 µl of serum/plasma or whole 
blood was dispensed into the test sample well, fol-
lowed by addition of 100 µl of diluent buffer provided 
in the kit. The results were visualized between 15 and 
20 minutes.
Ethics
The study was performed in accordance with the 
Declaration of Helsinki. Patients in all study cohorts 
included gave informed consent to serum donation 
and study participation. All studies were approved by 
the ethical review board: the COVID-19 prospective 
study (2020–01747); CPIP (472/2005); and MSAT 
(2015/593).
Statistic analysis
The data is presented in n (% of total) in respective 
analysis, and 95% confidence intervals for propor-
tions are calculated according to the Clopper– 
Pearson method.
Results
Qualitative COVID-19 IgM and IgG assessment in 
response to hospitalization in COVID-19 patients
A total of 45 COVID-19 patients confirmed with 
RT-PCR were enrolled at the Department for 
Infectious Diseases, Skåne University Hospital, 
Lund. In this cohort, 12 patients (27%) had more 
severe symptoms and were admitted to the hospital; 
33 patients (73%) had mild symptoms and were 
home quarantined. Sera from all patients were 
tested for COVID-19 IgM and IgG reactivity by 
a rapid COVID-19 antibody test (ZetaGene, 
Sweden). In 12 hospitalized patients, eleven (92%) 
were tested antibody positive to SARS-CoV-2, with 
9 (75%) positive for both IgM and IgG; two (17%) 
positive for IgG only (Figures 1 and 2; Table 1). In 
33 non-hospitalized patients, 26 (79%) were tested 
antibody positive, including 15 (45%) IgG positive 
IgM positive, one (3%) IgM positive only, and 10 
(30%) IgG positive only (Figures 1 and 2; Table 1). 
Together, the overall positive percentage agreement 
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(PPA) for COVID-19 antibody detection is 92% 
(95%CI: 62%-100%) for hospitalized patients, and 
79% (95%CI: 61%-91%) for non-hospitalized 
patients.
Qualitative COVID-19 IgM and IgG assessment in 
response to time after onset and hospitalization 
in COVID-19 patients
Previous studies revealed that COVID-19 seroconver-
sion for detectible IgM and IgG begins from the second 
week of symptom onset[6]. To better understand the 
dynamics of IgM/IgG detection in response to time 
after onset and hospitalization, the cohort patients 
were grouped into (1) acute patients with <2 weeks 
after onset of symptoms (n = 8, Table 2); (2) convales-
cent patients with >2 weeks after onset, non- 
hospitalized (n = 26, Table 3); (3) convalescent patients 
with >2 weeks after onset, hospitalized (n = 11, Table 4).
In sera from eight acute patients (seven non- 
hospitalized and one hospitalized) with less than 
2 weeks after onset, five patients were tested IgG 
and IgM positive (63%), and 3 were negative to 
IgG or IgM (37%, Figures 3 and 4, Table 2). The 
overall PPA for COVID-19 antibody detection in 
this subgroup is 63% (95%CI: 26%-90%).
In convalescent sera from 26 non-hospitalized 
patients with >2 weeks after onset, eleven (42%) were 
Figure 1. Serum SARS-Cov-2 IgM and IgG antibody detection in response to hospitalization in COVID-19 patients. IgM 
and IgG reactivity to SARS-CoV-2 was measured in sera in patients with PCR-confirmed COVID-19 (n = 45) by lateral flow test 
COVID-19 Antibody test IgM/IgG (ZetaGene, Sweden). Total IgM, IgG and total antibody detection percentage (%) are presented 
for the hospitalized (red bars, n = 12) and non-hospitalized patients (black bars, n = 33).
Figure 2. The distribution of COVID-19 IgM and IgG detection in hospitalized vs. non-hospitalized patients. Qualitative 
detection of IgM and IgG to SARS-CoV-2 was assessed in sera of hospitalized (n = 12) and non-hospitalized (n = 33) COVID-19 patients. 
IgG and IgM positivity and distribution (%) in the COVID-19 patients are presented in respective color as indicated in the figure.
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positive for both IgG and IgM, one (4%) was only IgM 
positive, 10 (38%) were only IgG positive, and 4 (15%) 
were IgG/IgM negative (Figures 3 and 4, Table 3). The 
overall PPA for COVDI-19 antibody detection was 
85% (95%CI: 65%-96%) for this subgroup.
In convalescent sera from 11 hospitalized patients 
with >2 weeks after onset, eight (73%) patients were 
positive for both IgG and IgM, and 2 (18%) were IgG 
positive only. There was also one (9%) patient with 
no detectible IgG or IgM (Figures 3 and 4, Table 4). 
The overall PPA in this subgroup for COVDI-19 
antibody detection was 91% (95%CI: 56%-100%).
The distribution of antibody detection in the above 
three groups of patients is 63%, 46%, and 73% for 
total IgM; 63%, 81%, and 91% for total IgG; and 63%, 
85%, and 91% for total antibody (Figure 3).
Among all individuals, three patients (ID 2, 5, and 
12) were tested at both <2 weeks and >2 weeks. 
Patients 2 and 5 were hospitalized at both samplings, 
and patient 12 was home quarantined. Patient 2 was 
IgG and IgM positive at first sampling, and converted 
to IgG positive IgM negative at the second sampling. 
Patient 5 was IgG and IgM positive at both time 
points. Patient 12 was antibody negative at 
<2 weeks, and converted to IgG and IgM positive at 
>2 weeks.
Comparison of antibody detection between whole 
blood, serum and plasma sampling
Serum and plasma antibody detection from the same 
individuals were compared in eight patients, and no 
difference between the two measurements was observed. 
We also compared serum and whole blood readout from 
19 patients. In 18 patients, serum and whole blood gave 
uniform antibody detection. However, in one patient, we 
observed that IgG positive was only detected in the 
serum but not in the whole blood.
Verification of IgM and IgG reactivity in 
pre-COVID-19 control cohorts
For accurate interpretation of the rapid IgM/IgG 
serology assessment of COVID-19 sera, and to deter-
mine the specificity of this rapid test, we performed 
qualitative measurements of IgM and IgG in two 
control cohorts with blood samples collected prior 
to the COVID-19 pandemic (2016–2018).
A healthy control cohort – MSAT cohort
The MSAT cohort includes healthy, well-trained males 
recruited for exercise tests conducted at the Department 
of Clinical Sciences, Malmö, Lund University, with the 
characteristics of age 37.4 ± 8.3 years [mean ± SD], BMI 
24.4 ± 2.4 kg/m2 [mean ± SD], and VO2MAX 
= 52.0 ± 8.1 ml/kg/min [mean ± SD].Thirty-nine 
serum samples collected between 2016 and 2017 were 
tested for COVID-19 IgM/IgG reactivity. Of 39 MSAT 
samples, 38 were tested negative for IgM or IgG, and 1 
was tested weak IgG positive.
The overall negative percentage agreement (NPA) for 
negative antibody detection is 97% (95%CI: 87%-100%).
Table 1. Serology assessment of COVID-19 IgG and IgM 
response by COVID-19 Antibody Test IgM/IgG (ZetaGene, 
Sweden) in sera collected from hospitalized (n = 12) and non- 
hospitalized (n = 33) PCR-confirmed COVID-19 patients.
Hospitalization Hospitalized Non-hospitalized
Positive IgG+/IgM+ 9 (75%) 15 (45%)
IgG-/IgM+ 0 (0%) 1 (3%)
IgG+/IgM- 2 (17%) 10 (30%)
Negative IgG-/IgM- 1 (8%) 7 (21%)
Subtotal 12 (100%) 33 (100%)
Total IgM% 9 (75%) 16 (49%)
Total IgG% 11 (92%) 26 (79%)
Total antibody% 92%* 79%**
*Positive percentage agreement (PPA) = 92% (95%CI: 62%-100%) 
**Positive percentage agreement (PPA) = 79% (95%CI: 61%-91%) 
Table 2. Serology assessment of COVID-19 IgG and IgM 
response by COVID-19 Antibody Test IgM/IgG (ZetaGene, 
Sweden) in PCR-confirmed COVID-19 patients with time 
after onset <2 weeks (n = 8).
<2 weeks after onset PCR-positive % of Total
Positive IgG+/IgM+ 5 63%
IgG-/IgM+ 0 0%
IgG+/IgM- 0 0%
Negative IgG-/IgM- 3 37%
Subtotal 8 100%
Total IgM% 5 63%
Total IgG% 5 63%
Total antibody% 5 63%
Positive percentage agreement (PPA) = 63% (95%CI: 26%-90%) 
Table 3. Serology assessment of COVID-19 IgG and IgM 
response by COVID-19 Antibody Test IgM/IgG (ZetaGene, 
Sweden) in PCR-confirmed non-hospitalized COVID-19 
patients with time after onset >2 weeks (n = 26).
>2 weeks after onset
PCR-positive % of TotalNon-hospitalized
Positive IgG+/IgM+ 11 42%
IgG-/IgM+ 1 4%
IgG+/IgM- 10 38%
Negative IgG-/IgM- 4 15%
Subtotal 26 100%
Total IgM% 12 46%
Total IgG% 21 81%
Total antibody% 22 85%
Positive percentage agreement (PPA) = 85% (95% CI: 65%-96%) 
Table 4. Serology assessment of COVID-19 IgG and IgM 
response by COVID-19 Antibody Test IgM/IgG (ZetaGene, 
Sweden) in PCR-confirmed hospitalized COVID-19 patients 
with time after onset >2 weeks (n = 11).
>2 weeks after onset Hospitalized PCR-positive % of Total
Positive IgG+/IgM+ 8 73%
IgG-/IgM+ 0 0%
IgG+/IgM- 2 18%
Negative IgG-/IgM- 1 9%
Subtotal 11 100%
Total IgM% 8 73%
Total IgG% 10 91%
Total antibody% 10 91%
Positive percentage agreement (PPA) = 91% (95%CI: 56%-100%) 
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A cardiovascular disease (CVD) control cohort – 
CPIP cohort
The CPIP cohort has continuous recruitment of patients 
since 2006 with advanced atherosclerosis and confirmed 
CVD at the Department of Clinical Sciences, Lund 
University. Thirty serum samples were randomly 
selected from the CPIP cohort, which include 10 samples 
from 2016, 10 from 2017 and 10 from 2018. The char-
acteristics of the individuals included in this study are as 
follows: age 71 ± 8 years [mean ± SD], BMI 27 ± 4 [mean 
± SD], 21 males and 9 females. Of the 30 samples, 29 
(97%) were tested negative for IgM or IgG, and 1 sample 
showed very weak IgM positive. The overall NPA for 
negative antibody detection is 97% (95%CI: 83%-100%).
By combining both MSAT and CPIP cohorts, we 
obtained an overall NPA for negative antibody detec-
tion 97% (95%CI: 90%-100%).
Discussion
In the global response to fight the COVID-19 pan-
demic, it remains crucial to profile the true popula-
tion epidemic, and provide knowledge on the nature 
of protection by acquired active immunity. This is 
Figure 3. The distribution of antibody detection in response to time from onset and hospitalization. Total IgM, IgG and 
total antibody detection percentage (%) are presented for PCR-confirmed COVID-19 patients divided into the following groups: 
(1) acute patients with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized 
(n = 26); (3) convalescent patients with > 2 weeks after onset, hospitalized (n = 11). Different groups are presented in respective 
colors as indicated in the figure.
Figure 4. The dynamics of COVID-19 IgM/IgG detection in response to time from onset and hospitalization. Qualitative 
detection of IgM and IgG to SARS-CoV-2 is mapped in COVID-19 cohort patients from the following groups: (1) acute patients 
with < 2 weeks (w) after onset (n = 8); (2) convalescent patients with > 2 weeks after onset, non-hospitalized (n = 26); (3) 
convalescent patients with > 2 weeks after onset, hospitalized (n = 11). IgM and IgG detection percentage (%) is presented in 
respective color as indicated in the figure.
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especially important in preparation for lifting con-
finement restrictions and preventing potential new 
waves of SARS-CoV-2 spread. Serological testing of 
COVID-19 antibody response is therefore a critical 
component in overcoming the pandemic. In this 
study, we performed detailed serology assessment 
on SARS-CoV-2 antibody response in patients with 
COVID-19 by a rapid IgM/IgG test. We compared 
different blood sample types and evaluated antibody 
responses in relation to the time from onset and 
hospitalization. Furthermore, we verified test specifi-
city in control cohorts recruited prior to the COVID- 
19 pandemic.
Recent studies reveal that the spike glycoprotein (S) of 
SARS-CoV-2 mediates receptor binding on host cells, 
membrane fusion, and virus entry. Additionally, it is the 
main target for neutralizing antibodies[7]. Each mono-
mer of trimeric S protein contains two subunits, S1 and 
S2, mediating attachment and membrane fusion, respec-
tively, with the S1 region being the major immune- 
epitope for antibody binding. In this study, we employed 
a lateral flow test that detects antibodies binding to the 
receptor-binding domain (RBD) of S1 protein. The test 
offers qualitative assessment and indicates the presence 
or absence of SARS-CoV-2 antibodies. The test has been 
previously evaluated on 38 COVID-19 hospitalized 
patients and 228 healthy controls during Wuhan 
COVID-19 outbreak in China, and achieved 
a sensitivity and a specificity of 95% and 97% (www. 
zetagene.com). In the current study, we observed that 
92% of hospitalized patients have detectable antibodies, 
which is similar to the clinical validation in China 
(unpublished). The negative test results may be explained 
by a combination of test sensitivity, the complexity of 
antibody development biology, as well as the heterogene-
ity in antibody titres among individuals.
A previous study revealed that IgM kinetics is notably 
different between COVID-19 ICU and non-ICU patients. 
In patients with mild symptoms, IgM levels start to 
decline after 2 weeks while IgG continues to increase, 
while in patients with severe symptoms, IgM levels 
remains static or increases even after 4 weeks[8]. In our 
study, IgM was detected in 49% of non-hospitalized con-
valescent patients, and 75% in hospitalized patients 
(Figure 1). This observation suggests that IgM may be 
present in the blood for a longer period in hospitalized 
patients. Furthermore, it has been shown that high titers 
of IgG antibodies positively correlate with neutralizing 
antibodies[9]. In our study we also observed higher pre-
valence of IgG-only detection in non-hospitalized vs. 
hospitalized convalescent patients (30% vs. 17%,Table 
1). Furthermore, we mapped a clear increase in the anti-
body response from early disease onset (<2 weeks, 63%) 
to a later time point (>2 weeks, 85% and 91%, in non- 
hospitalized and hospitalized patients, respectively, Figs. 
3 and 4), which is in line with the antibody development 
profile following COVID-19 progression and an earlier 
investigation in Sweden[10].
A previous study on COVID-19 recovered patients 
showed that there is a heterogeneity in antibody titers 
among the recovered patients, and around 15% of recov-
ered patients had very low antibody titers or even levels 
below the threshold of detection[11]. This observation is 
also in line with our study on recovered patients, where 
we observed that 85% of non-hospitalized recovered 
patients and 91% of hospitalized recovered patients had 
detectable COVID-19 antibodies (Figure 3).
We compared antibody detection in whole blood, 
serum, and plasma. In one patient out of 19 patients, 
IgG positivity was only detected in serum but not in 
whole blood. Also, upon comparison of the sensitivity 
in serum versus plasma, we did not observe any 
difference in the eight patients where both plasma 
and serum were analyzed. Albeit suggestive, clinical 
assessment of COVID-19 antibody reactivity per-
formed on serum/plasma is likely to be more accurate 
than that of whole blood. Further evaluation is 
needed to compare pinprick blood, whole blood, 
and serum/plasma sensitivity.
The choice of negative control cohorts also warrants 
explanation. The COVID-19 pandemic was reported to 
have reached Sweden on 31 January 2020 with the first 
clinically confirmed case[12]. The epidemic outbreak of 
COVID-19 in Sweden started on 26 February, with con-
firmed community transmission on 9 March in the 
Stockholm region. However, according to the Public 
Health Agency of Sweden, it is likely that there were 
individual cases of COVID-19 in Sweden as early as 
November 2019. Therefore, we chose to use cohorts 
with blood samples collected before 2019 as the negative 
controls of the test. We tested both a healthy cohort and 
a diseased cohort with cardiovascular morbidity, and 
both cohorts displayed uniform specificity.
In summary, our study provides a comprehensive 
validation of the rapid COVID-19 IgM/IgG serology 
assessment. Also, the antibody detection patterns in 
association with disease progress and hospitalization 
was mapped, which provides a potential reference for 
accurate clinical antibody assessment interpretation. 
The rapid COVID-19 IgM/IgG test may be a valuable 
application for COVID-19 clinical diagnosis, and can 
be applied as a powerful tool to assess the COVID-19 
status at both individual and population level.
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